Brainstorm Cell Therapeutics Inc.
BCLI· OTC
BCLIBrainstorm Cell Therapeutics Inc.
Filed Aug 5, 2021 · 10-Q · 36 days after period end · 0001104659-21-100414
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Net Income | -$6.27M | -$7.39M | -$4.90M | -$3.09M |
| EPS Diluted | -$0.17 | — | — | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Brainstorm Cell Therapeutics Inc. · CIK 1137883 · Engraved from SEC EDGAR
ended Jun 30, 2021 · filed Aug 5, 2021 · 36 d after period end
